Spirocyclic heterocycle compounds useful as HIV integrase inhibitors

Patent metadata

Field	Value
Publication number	US-10150780-B2
Application number	US-201515533068-A
Country	US
Kind code	B2
Filing date	Dec 4, 2015
Priority date	Dec 9, 2014
Publication date	Dec 11, 2018
Grant date	Dec 11, 2018

Abstract

The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, X, R 1 , R 2 , R 3 and R 4 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

First claim

What is claimed is:

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof,
wherein:
A is —NHC(O)—;
B is C 3 -C 6 cycloalkyl or 3 to 8-membered heterocycloalkyl, which can be optionally substituted with R 5 ;
X is CH 2 ;
R 1 is —N(C 1 -C 6 alkyl) 2 or R 1 and an R 3 group, together with the atoms to which they are attached, combine to form a 4 to 7-membered heterocycloalkyl, which can be optionally substituted with R 5 ;
R 2 represents up to 3 optional substitutents, each independently selected from halo, C 1 -C 6 alkyl, —O—(C 1 -C 6 alkyl) and C 1 -C 6 haloalkyl;
each occurrence of R 3 is independently selected from H, C 1 -C 6 alkyl, —OH, —O—(C 1 -C 6 alkyl), C 1 -C 6 haloalkyl, C 3 -C 7 cycloalkyl, —S—(C 1 -C 6 alkyl), —NH 2 , —NH(C 1 -C 6 alkyl) and —N(C 1 -C 6 alkyl) 2 ;
R 4 is H;
R 5 represents one or more groups, each independently selected from halo, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, 3 to 8-membered monocyclic heterocycloalkyl, 6 to 10-membered bicyclic heterocycloalkyl, —O—(C 1 -C 6 alkyl), —O—(C 6 -C 10 aryl), —O—(C 1 -C 6 alkylene)-O—(C 1 -C 6 alkyl), —O—(C 1 -C 6 haloalkyl), —O—(C 1 -C 6 alkylene)-O—(C 1 -C 6 alkylene)-O—(C 1 -C 6 alkyl), —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —S(O) 2 (C 1 -C 6 alkyl), —NHS(O) 2 —(C 1 -C 6 alkyl), —S(O) 2 NH—(C 1 -C 6 alkyl), —OC(O)—(C 1 -C 6 haloalkyl), —(C 1 -C 6 alkylene) p -C(O)O—(C 1 -C 6 alkyl), —(C 1 -C 6 alkylene) p -C(O)—(C 1 -C 6 alkyl), —(C 1 -C 6 alkylene) p -C(O)N(R 6 ) 2 , C 1 -C 6 hydroxyalkyl, —P(O)(OR 8 ) 2 , and —CN;
each occurrence of R 6 is independently selected from H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 haloalkyl and —(C 1 -C 6 alkylene) p -R 7 ;
each occurrence of R 7 is independently selected from H, C 1 -C 6 alkyl, —O—(C 1 -C 6 alkyl), C 3 -C 7 cycloalkyl, 5- or 6-membered monocyclic heteroaryl and 3 to 8-membered monocyclic heterocycloalkyl;
each occurrence of R 8 is independently selected from H and C 1 -C 6 alkyl; and
each occurrence of p is independently 0 or 1.

2. The compound of claim 1 , having the formula:

or a pharmaceutically acceptable salt thereof,
wherein:
A is —NHC(O)—;
B is C 3 -C 6 cycloalkyl or 3 to 8-membered heterocycloalkyl, each of which can be optionally substituted with R 5 ;
each occurrence of R a is independently C 1 -C 6 alkyl;
R 2 represents up to 3 optional substituents, each independently selected from halo; and
R 3 is H or C 1 -C 6 alkoxy.

3. The compound of claim 2 , wherein R 3 is methoxy, or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , having the formula:

or a pharmaceutically acceptable salt thereof,
wherein:
A is —NHC(O)—;
B is C 3 -C 6 cycloalkyl or 3 to 8-membered heterocycloalkyl, each of which can be optionally substituted with R 5 ;
Z is 4 to 7-membered monocyclic heterocycloalkyl, which can be optionally substituted with R 5 ; and
R 2 represents up to 3 optional substituents, each independently selected from halo.

5. The compound of claim 4 , wherein Z is a 6-membered heterocycloalkyl-, or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein B is C 3 -C 6 cycloalkyl, or a pharmaceutically acceptable salt thereof.

7. The compound of claim 6 , wherein B is cyclopropyl, or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , wherein R 2 represents up to 3 substituent groups, each independently selected from F and Cl, or a pharmaceutically acceptable salt thereof.

9. The compound of claim 8 , wherein R 2 and the phenyl group to which R 2 is attached is selected from:

or a pharmaceutically acceptable salt thereof.

10. A compound selected from:

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. A method for the inhibition of HIV integrase in a subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

13. A method for the treatment of infection by HIV or for the treatment, or delay in the onset or progression of AIDS in a subject in need thereof, which comprises administering to the subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

14. The pharmaceutical composition of claim 11 , further comprising one or more additional therapeutic agents selected from raltegravir, lamivudine, abacavir, ritonavir, dolutegravir, arunavir, atazanavir, emtricitabine, tenofovir, elvitegravir, rilpivirine and lopinavir.

15. The method of claim 13 , further comprising administering to the subject one or more additional therapeutic agents selected from raltegravir, abacavir, lamivudine, ritonavir and lopinavir, wherein the amounts administered of the compound of claim 1 and the one or more additional therapeutic agents, are together effective to treat infection by HIV or to treat, prevent or delay the onset or progression of AIDS.

Assignees

• Merck Sharp & Dohme

Inventors

• Graham Thomas H
• Embrey Mark W
• Walji Abbas
• Waddell Sherman T

Classifications

• C07D498/14 Primary

  Ortho-condensed systems · CPC title

• C07D491/20

  Spiro-condensed systems · CPC title

• A61K31/7072

  having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine · CPC title

• A61K31/635

  having a heterocyclic ring, e.g. sulfadiazine · CPC title

• A61K31/52

  Purines, e.g. adenine · CPC title